Feasibility assessment of in vitro chemoresponse assay on stereotactic biopsies of glioblastoma multiforms: a step towards personalized medicine


1 Health Management Department, Quality Assurance Deputy, Razi Vaccine & Serum Research Institute, Karaj, Iran

2 Cancer Models Research Center, Cancer Institute of Iran, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Neurosurgery, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

4 Research Center for Molecular and Cellular Imaging, Tehran University of Medical Sciences, Tehran, Iran

5 Anatomy Department, School of Medicine, Tarbiat Modares University, Tehran, Iran

6 Omid Institute for Advance Biomodels, Incubation Center for Medical Devices, Tehran University of Medical Sciences, Tehran, Iran

7 Virology Department, Pasteur Institute of Iran, Tehran, Iran


Objective(s):P In vitro chemosensitivity and resistance assays (CSRAs) are a promising tool for personalized treatment of glioblastoma multiform (GBM). These assays require a minimum of 1 to 2 g of tumor specimen for testing, but this amount is not always accessible. We aimed to assess the feasibility and validity of utilizing stereotactic biopsies of GBM in CSRAs.
Materials and Methods: Single cell suspension was prepared from 1 g weight explants of the established xenograft tumor of GBM. Also, primary culture was carried out on 35 mg weight specimens, as a surrogate for stereotactic biopsies. Then, chemoresponse profile of cells obtained by direct cell disaggregation and primary culture was determined using temozolomide and carmustine by clonogenic assay[AGA1] .
Results: There was no statistically significant difference in the cytotoxicity of temozolomide and carmustine between cells obtained from both methods.
Conclusion: This work supports the feasibility of using stereotactic biopsies of GBM in CSRAs.


1.  Schuwartzbaum JA, Fisher JL, Aldape KD, Wrensch M. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol 2006; 2:494-503.
2. Castro MG, Cowen R, Williamson IK, David A, Jimenez-Dalmaroni MJ, Yuan X, et al. Current and future strategies for the treatment of malignant brain tumors. Pharmacol Ther 2003; 98:71-108.
3. Cohen MH, Shen YL, Keegan P, Pazdur R. FDA drug approval summary: bevacizumab (Avastin) as treatment of recurrent glioblastoma multiform. Oncologist 2009; 14:1131-1138.
4. Li J, Di C, Mattox AK, Wu L, Adamson DC . The future role of personalized medicine in the treatment of glioblastoma multiform. Pharmacogenomics Pers Med 2010; 3:111-127.
5. Meric-Bernstam F, Mills GB. Overcoming implemen-
tation challenges of personalized cancer therapy. Nat Rev Clin Oncol 2012; 9:542-548.
6. Brower SL, Fensterer JE, Bush JE. The ChemoFx assay: an ex vivo chemosensitivity and resistance assay for predicting patient response to cancer chemotherapy. Methods Mol Biol 2008; 414:57-78.
7. Brown E, Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer 1996; 77:1020-1025.
8. Hamburger AW, Salmon SE.  Primary bioassay of human tumor stem cells. Science 1977; 197:461-463.
9. Fiebig HH, Maier A, Burger AM. Clonogenic assay with established human tumor xenografts: correlation of in vitro to in vivo activity as a basis for anticancer drug discovery. Eur J Cancer 2004; 40:802-820.
10.  Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, et al. Limitations of stereotactic biopsies in the initial management of gliomas. Nero Oncol 2001; 3:193-200.
11. Mi Z, Holmes FA, Hellerstedt B, Pippen J, Collea              R, Backner A, et al. Feasibility assessment of chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients. Anticancer Res 2008; 28:1733-1740.
12. Negrini S, Gorgoulis VG, Halazonetis TD.  Genomic instability-an evolving hallmark of cancer. Nar Rev Mol Cell Biol 2010; 11:220-228.
13. Ochs RL, Fensterer J, Ohori NP, Wells A, Gabrin M, George LD, et al. Evidence for the isolation, growth, and characterization of malignant cells in primary cultures of human tumors. In Vitro Cell Dev Biol Anim 2003; 30:63-70.
14. Gallion H, Christopherson WA, Coleman RL, DeMars L, Herzog T, Hosford S, et al. Progression-free interval in ovarian cancer and predictive value of an ex vivo chemoresponse assay. Int J Gynecol Cancer 2006; 16:194-201.
15. Mohd Ramli SZ, Shamsuddin S, Norliza Hassan N, Alias A, Mohd Haspani MS, Abdullah J. Molecular targets of CNS tumors. In: Garami M (eds). Shanghai: InTech; 2011. p: 439-458.